Genetic and pharmacologic inhibition of ALDH1A3 as a treatment of β-cell failure

Jinsook Son; Wen Du; Mark Esposito; Kaavian Shariati; Hongxu Ding; Yibin Kang; Domenico Accili

doi:10.1038/s41467-023-36315-4

Nature Communications (Feb 2023)

Genetic and pharmacologic inhibition of ALDH1A3 as a treatment of β-cell failure

Jinsook Son,
Wen Du,
Mark Esposito,
Kaavian Shariati,
Hongxu Ding,
Yibin Kang,
Domenico Accili

Affiliations

Jinsook Son: Department of Medicine and Naomi Berrie Diabetes Center, Vagelos College of Physicians and Surgeons, Columbia University
Wen Du: Department of Medicine and Naomi Berrie Diabetes Center, Vagelos College of Physicians and Surgeons, Columbia University
Mark Esposito: Kayothera Inc
Kaavian Shariati: Department of Medicine and Naomi Berrie Diabetes Center, Vagelos College of Physicians and Surgeons, Columbia University
Hongxu Ding: Department of Pharmacy Practice & Science, College of Pharmacy, University of Arizona
Yibin Kang: Department of Molecular Biology, Princeton University
Domenico Accili: Department of Medicine and Naomi Berrie Diabetes Center, Vagelos College of Physicians and Surgeons, Columbia University

DOI: https://doi.org/10.1038/s41467-023-36315-4
Journal volume & issue: Vol. 14, no. 1
pp. 1 – 14

Abstract

Read online

β-cell dedifferentiation is a key feature of type 2 diabetes. Here, the authors show evidence of re-differentiation of de-differentiated β-cells and identify ALDH1A3 as a key player in this process, proposing inhibition of ALDH1A3 as a treatment method for β-cell dysfunction in diabetes.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal